Trial Profile
Proof of Concept Study to Compare Efficacy and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants and Narrow-Band Ultraviolet B (NB-UVB) Light Versus NB-UVB Light Alone in the Treatment of Nonsegmental Vitiligo
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jun 2015
Price :
$35
*
At a glance
- Drugs Afamelanotide (Primary)
- Indications Vitiligo
- Focus Proof of concept; Therapeutic Use
- Sponsors Clinuvel Pharmaceuticals
- 17 Apr 2014 New trial record